Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Description:
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma. On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy...